このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

幻肢痛に対する仮想現実治療の有効性とメカニズム

2026年9月8日 更新者:Laurel Buxbaum、Albert Einstein Healthcare Network

幻肢痛のバーチャルリアリティ治療の有効性とメカニズム:対面治療

After amputation of an arm or leg, up to 90% of subjects experience a "phantom limb", a phenomenon characterized by persistent feelings of the missing limb. Many subjects with a phantom limb experience intense pain in the missing extremity that is often poorly responsive to medications or other interventions. The proposed work will contrast the efficacy of two virtual reality treatments for phantom limb pain: a 'Distractor' and an Active VR treatment. In the Distractor treatment, participants are engaged in a visually immersive virtual reality experience that does not require leg movements (REAL i-Series® immersive VR experience). In the Active VR treatment, subjects play a series of VR games using the virtual rendering of both legs.

調査の概要

状態

完了

条件

詳細な説明

Almost 2 million people in the US have had an amputation and up to 90% of people with limb amputation experience the persistent sensation of the missing extremity, a phenomenon known as a "phantom limb" (Weeks et al., 2010). Additionally, a significant proportion of individuals with a phantom limb - up to 85% in some studies - experience persistent and debilitating pain in the missing limb, a condition known as phantom limb pain (hereafter PLP). Although existing therapies provide pain relief in some cases, there is widespread agreement that current approaches fall short of bringing relief to most individuals with PLP (Weeks et al., 2010).

The investigators recently completed a proof-of-concept study (Ambron et al., 2021) in which eight subjects with below knee amputations (BKA) underwent two virtual reality (VR) treatments for PLP. In an Active VR treatment, subjects played a variety of active games requiring leg movements while receiving high-quality visual feedback of the missing lower leg. Feedback about leg position was provided via an electromagnetic system using leg sensors (trackSTAR, Ascension Technologies Inc), and the program generated an image of the missing lower leg, visible as a first-person avatar. This treatment was contrasted with a "Distractor" treatment, in which participants were engaged in a visually immersive virtual reality experience that did not require leg movements (Cool!TM). Both treatments were associated with significant reductions in pain intensity, but the Active VR treatment was also associated with reductions in pain interference, depression, and anxiety.

The specific aims of the current study are (i) to replicate our prior observations of efficacy of VR treatment in a larger sample of individuals with BKA; (ii) to test VR therapy in patients with above knee amputations; (iii) to compare the efficacy of Active VR treatment to Distractor VR treatment for PLP on measures of pain as well as psychological health and quality of life.

研究の種類

介入

入学 (実際)

46

段階

  • 適用できない

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究場所

    • Pennsylvania
      • Elkins Park、Pennsylvania、アメリカ、19027
        • Moss Rehabilitation Research Institute
      • Philadelphia、Pennsylvania、アメリカ、19104
        • University of Pennsylvania
    • Washington
      • Seattle、Washington、アメリカ、98104
        • University of Washington-Harborview Medical Center

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

18年~100年 (大人、高齢者)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

説明

Inclusion Criteria:

  1. Age 18 - 100 years
  2. Capacity to provide Informed Consent
  3. Unilateral above or below knee amputation more than 3 months prior to enrollment
  4. Absence of cognitive impairment, operationally defined as a Montreal Cognitive Assessment score of 18 or greater
  5. Pain averaged over the preceding 1 month in the phantom limb rated as greater than 4 on a scale of 0-10.

Exclusion Criteria:

  1. History of significant medical or neurological disorder such as stroke or moderate to severe traumatic brain injury (operationally defined as loss of consciousness for more than 30 minutes)
  2. History of significant or poorly controlled psychiatric disorders
  3. Current significant depression or anxiety as judged by the Hospital Anxiety and Depression Scale (HADS) (Zigmond & Snaith, 1983).
  4. Current abuse of alcohol or drugs, prescription or otherwise
  5. Nursing a child, pregnant, or intent to become pregnant during the study

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:処理
  • 割り当て:ランダム化
  • 介入モデル:並列代入
  • マスキング:なし(オープンラベル)

武器と介入

参加者グループ / アーム
介入・治療
実験的:Active VR treatment

Subjects assigned to the Active VR treatment began by selecting an avatar, with features such as gender and skin color that could be chosen according to preference. During treatment, they participated in a variety of games and activities developed and used by our teams including Kick, Dog Food, Quest for Fire, Chess, Checkers, Sudoku, and surfing the internet. Subjects had substantial flexibility to select games according to their interests but were required to spend at least 30 minutes in each session in games that required forceful, large-amplitude movements of the amputated lower limb (e.g., Quest for Fire, Kick).

8 twice-weekly interventions of virtual reality treatment focused on reducing phantom limb pain.

実験的:Distractor VR treatment

Subjects assigned to the Distractor VR treatment participated in the REAL i-Series immersive VR experience (REAL system), which had been demonstrated to reduce pain in several studies but lacked the hypothesized "active ingredients" of our Active VR treatment (visual and auditory feedback of movement of an extrapolated amputated limb). Subjects navigated through pleasant and relaxing VR environments; they did not see any rendering of their body and made no movements with their legs.

8 twice-weekly interventions of virtual reality treatment focused on reducing phantom limb pain.

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Changes in Pain Intensity
時間枠:Baseline versus immediately post-intervention at 4 weeks.

Visual Analogue Scale (VAS) of McGill Short Form Questionnaire (Melzack, 1987); 0 minimum score - 10 maximum score; higher scores indicate higher level of pain (worse outcome)

Baseline versus immediately post-intervention at 4 weeks.
Changes in Pain Quality
時間枠:Baseline versus immediately post-intervention at 4 weeks.

McGill Short Form Questionnaire (Melzack, 1987): a series of 4-point scales (0 none - 3 severe) assessing the intensity of 15 qualitative characteristics of pain (e.g., throbbing, shooting, cramping, etc.), where higher scores are worse (more severe). For every participant we computed the total pain score (maximum 45 points indicating severe pain). Then, we computed the difference in the total scores between time points (e.g. post treatment vs baseline). Therefore, negative scores indicate improvement in pain qualitative characteristics.

Baseline versus immediately post-intervention at 4 weeks.

二次結果の測定

結果測定
メジャーの説明
時間枠
Changes in Average Pain
時間枠:1st treatment versus 8th treatment (4 weeks)

Difference between 8th and 1st treatment session on scaled score measuring "average pain intensity since the previous intervention" on an 11-point numerical rating pain scale; (Scale = 0 - minimum score/no pain to 10 maximum score/pain as bad as participants can imagine); higher scores indicate higher level of pain (worse outcome).

1st treatment versus 8th treatment (4 weeks)

その他の成果指標

結果測定
メジャーの説明
時間枠
Changes in Daily Activities
時間枠:Baseline versus immediately post-intervention at 4 weeks.

The Frenchay Activities Index (FAI) (Holbrook et al., 1983):1983): a scale measuring the physical function and daily activity associated with quality of life in people with amputation. Scale = 0 minimum score to 45 maximum score; higher scores indicate more daily activities (better outcome). We report the average difference between post-intervention (after 4 weeks) and pre-intervention.

Baseline versus immediately post-intervention at 4 weeks.
Changes in Quality of Life
時間枠:Baseline versus immediately post-intervention at 4 weeks.

The 12-Item Short Form Health Survey (SF-12) (Ware et al., 1996): a measure of quality of life and functional capacity that has been validated in patients with amputation and phantom limb pain. Scale = 0 minimum score to 100 maximum score. Higher scores indicate poorer physical and mental health (worse outcome).

Baseline versus immediately post-intervention at 4 weeks.
Changes in Pain Interference
時間枠:Baseline versus immediately post-intervention at 4 weeks

The Pain Interference Scale from the Brief Pain Inventory (BPI) (Cleeland & Ryan, 1994): A scale measuring the degree to which pain interferes with daily activities using a 0-10 numeric rating. Scale = 0 minimum score to 10 maximum score. Higher scores indicate greater pain interference (worse outcome). We report the average difference between post-intervention (after 4 weeks) and pre-intervention.

Baseline versus immediately post-intervention at 4 weeks
Changes in Depression and Anxiety
時間枠:Baseline versus immediately post-intervention at 4 weeks.

The Hospital Anxiety and Depression Scale (HADS) (Zigmond & Snaith, 1983): This is a 14- item measure with subscales assessing depressive and anxiety symptoms. For each subscale. range = 0 minimum score to 42 maximum score. Higher scores indicate more depression and/or anxiety (worse outcome). We report average differences on the anxiety scale and the depression scales between post-intervention (after 4 weeks) and pre-intervention.

Baseline versus immediately post-intervention at 4 weeks.
Changes in Pain Catastrophizing
時間枠:Baseline versus immediately post-intervention at 4 weeks.

The 13-item Pain Catastrophizing Scale (Sullivan et al., 1995): this scale investigates pain catastrophizing, which has been associated with pain severity and disability after amputation. Score range = 0-52; Higher scores indicate higher tendency to catastrophize (worse outcome). We report the average difference between post-intervention (after 4 weeks) and pre-intervention.

Baseline versus immediately post-intervention at 4 weeks.
Changes in Insomnia
時間枠:Baseline versus immediately post-intervention at 4 weeks.

Insomnia Severity Index (Bastien et al., 2001): a 7-point scale that measures insomnia, a symptom associated with phantom limb pain. Score range = 0-28; higher scores indicate more insomnia (worse outcome). We report the average difference between post-intervention (after 4 weeks) and pre-intervention.

Baseline versus immediately post-intervention at 4 weeks.
Acceptance of VR System
時間枠:Baseline

Technology Acceptance Scale (Morris et al., 1997): this is a 7-point scale that measures level of acceptance of the VR system. 0 minimum score - 133 maximum score; higher scores indicate low level of acceptance (worse score).

Baseline
Usability of the Treatment
時間枠:immediately after the last intervention (session 8 of the intervention), an average of 4 weeks

System Usability Scale (SUS) (Brooke, 1996); Scale measuring the usability of the each game; minimum score 10 - maximum score 50. Higher scores indicate less usability (worse outcome). For the distractor treatment, participants rated the overall experience; for the active treatment, the average of the two games was computed for each participants.

immediately after the last intervention (session 8 of the intervention), an average of 4 weeks
Cybersickness
時間枠:1st (week 1) and 8th (week 4) treatment sessions

Simulator Sickness Questionnaire - SSQ (Kennedy et al., 1993): 4 points (0 - none; 3 - severe) scale assessing the severity of 16 cybersickness motion sickness symptoms, like nausea or dizziness. We computed the average score across items.

1st (week 1) and 8th (week 4) treatment sessions
Presence in VR
時間枠:1st (week 1) and 8th (week 4) treatment sessions.

Brief Slater-Usoh-Steed Presence Questionnaire (Usoh et al., 2000; Slater et al., 1998; 1994). 0 minimum score - 42 maximum score. Higher scores indicate more presence in the VR (better outcome

1st (week 1) and 8th (week 4) treatment sessions.
Changes in Pain at Its Worst
時間枠:Baseline versus immediately post-intervention at 4 weeks

The Modified Limb Deficiency and Phantom Limb Questionnaire (Goller et al., 2013): a questionnaire and visual analog scale assessing prosthesis usage, phantom limb experiences, and pain severity. The outcome measure used was the score on the visual analogue scale assessing pain severity at its worst (Scale = 0 no pain to 10 unbearable pain). We report the average score difference between post-intervention (after 4 weeks) and pre-intervention.

Baseline versus immediately post-intervention at 4 weeks
Treatment Satisfaction
時間枠:1 week after the end of the intervention, an average of 5 weeks

Visual analogue scale that evaluates treatment satisfaction (Robinson et al., 2004; Smith et al., 2005); 0 minimum score - 10 maximum score; Higher scores indicate more treatment satisfaction (better outcome)

1 week after the end of the intervention, an average of 5 weeks

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

捜査官

  • 主任研究者:Laurel Buxbaum, PsyD、Albert Einstein Healthcare Netork

出版物と役立つリンク

研究に関する情報を入力する責任者は、自発的にこれらの出版物を提供します。これらは、研究に関連するあらゆるものに関するものである可能性があります。

一般刊行物

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2022年5月10日

一次修了 (実際)

2025年3月16日

研究の完了 (実際)

2025年4月6日

試験登録日

最初に提出

2022年2月9日

QC基準を満たした最初の提出物

2022年3月24日

最初の投稿 (実際)

2022年3月25日

学習記録の更新

投稿された最後の更新 (実際)

2026年9月30日

QC基準を満たした最後の更新が送信されました

2026年9月8日

最終確認日

2026年9月1日

詳しくは

本研究に関する用語

その他の研究ID番号

  • 2022-775.
  • 5R01HD104158-05 (米国 NIH グラント/契約)

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

はい

IPD プランの説明

After de-identification, individual participant data to be shared included descriptors of clinical status (e.g., time since amputation, level of amputation), background test battery results, and outcome measures results.

IPD 共有時間枠

Immediately following publication. No end date.

IPD 共有アクセス基準

Researchers who provide a sound rationale.

IPD 共有サポート情報タイプ

  • STUDY_PROTOCOL

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する